Tudor Investment Corp ET AL Has $4.76 Million Stock Position in Alignment Healthcare, Inc. $ALHC

Tudor Investment Corp ET AL reduced its position in Alignment Healthcare, Inc. (NASDAQ:ALHC) by 76.0% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 273,010 shares of the company’s stock after selling 865,720 shares during the period. Tudor Investment Corp ET AL’s holdings in Alignment Healthcare were worth $4,764,000 as of its most recent filing with the SEC.

Other hedge funds have also bought and sold shares of the company. Larson Financial Group LLC acquired a new stake in Alignment Healthcare in the 3rd quarter valued at about $33,000. Wilmington Savings Fund Society FSB acquired a new stake in Alignment Healthcare in the 3rd quarter valued at about $53,000. PNC Financial Services Group Inc. lifted its stake in Alignment Healthcare by 205.6% in the 3rd quarter. PNC Financial Services Group Inc. now owns 3,459 shares of the company’s stock valued at $60,000 after purchasing an additional 2,327 shares during the last quarter. Allworth Financial LP lifted its stake in Alignment Healthcare by 28.3% in the 3rd quarter. Allworth Financial LP now owns 6,351 shares of the company’s stock valued at $111,000 after purchasing an additional 1,402 shares during the last quarter. Finally, Wexford Capital LP acquired a new stake in Alignment Healthcare in the 3rd quarter valued at about $164,000. 86.19% of the stock is currently owned by institutional investors and hedge funds.

Alignment Healthcare Stock Performance

Shares of ALHC stock opened at $21.31 on Thursday. The company has a market capitalization of $4.35 billion, a price-to-earnings ratio of -2,128.87, a PEG ratio of 2.74 and a beta of 1.20. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.71 and a current ratio of 1.71. The company has a 50-day simple moving average of $19.36 and a 200 day simple moving average of $18.97. Alignment Healthcare, Inc. has a 52 week low of $11.63 and a 52 week high of $23.87.

Alignment Healthcare (NASDAQ:ALHC) last announced its earnings results on Thursday, February 26th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.10. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Alignment Healthcare had a negative net margin of 0.02% and a negative return on equity of 0.49%. Alignment Healthcare’s revenue was up 44.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.16) EPS. On average, sell-side analysts predict that Alignment Healthcare, Inc. will post -0.69 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on ALHC. UBS Group raised their target price on shares of Alignment Healthcare from $18.00 to $21.00 and gave the company a “neutral” rating in a research note on Wednesday, January 14th. TD Cowen raised their target price on shares of Alignment Healthcare from $18.50 to $25.00 and gave the company a “buy” rating in a research note on Friday, January 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alignment Healthcare in a research note on Wednesday, January 21st. Wall Street Zen downgraded shares of Alignment Healthcare from a “buy” rating to a “hold” rating in a report on Saturday, March 7th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Alignment Healthcare from $23.00 to $26.00 and gave the stock an “overweight” rating in a report on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $24.75.

Insider Transactions at Alignment Healthcare

In other Alignment Healthcare news, insider Robert L. Scavo sold 11,285 shares of the business’s stock in a transaction dated Wednesday, March 18th. The shares were sold at an average price of $17.84, for a total value of $201,324.40. Following the completion of the sale, the insider owned 487,685 shares of the company’s stock, valued at $8,700,300.40. The trade was a 2.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO John E. Kao sold 250,000 shares of the business’s stock in a transaction dated Tuesday, April 7th. The shares were sold at an average price of $21.01, for a total transaction of $5,252,500.00. Following the completion of the sale, the chief executive officer directly owned 2,104,641 shares of the company’s stock, valued at $44,218,507.41. This represents a 10.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 1,356,097 shares of company stock worth $26,365,919. Company insiders own 7.00% of the company’s stock.

About Alignment Healthcare

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.